#ADA25: Lilly’s bimagrumab boosts weight and fat loss when added to Novo’s Wegovy
Eli Lilly’s muscle-boosting drug allowed obese patients who are taking Novo Nordisk’s Wegovy to retain almost all of their lean tissue, according to data presented Monday. The data are from a Phase 2b trial called …
Shiru invites brands to harness its AI platform to explore ‘natural’ GLP-1 activation: ‘The opportunity is immense’ – AgFunderNews
Shiru invites brands to harness its AI platform to explore ‘natural’ GLP-1 activation: ‘The opportunity is immense’ AgFunderNews
STAT+: Eli Lilly drug preserves lean mass in patients losing weight on Wegovy
CHICAGO — An investigational therapy from Eli Lilly helped preserve lean mass and drive greater loss of fat in patients taking the popular obesity treatment Wegovy. In a Phase 2 trial, patients taking the highest-dose combination of Wegovy and the drug, called bimagrumab, lost 22% of their weight at 72 weeks. Ninety-three percent of that […]
How to lose weight before your summer holiday without jabs on the ‘BB’ plan – including the top 5 ‘Nozempic’ foods
THE thought of putting a bikini on fills many of us with dread. But some simple lifestyle tweaks can give you a much-needed pre-holiday confidence boost, and help you slim down, sleep better, de-bloat and stress less in the process. instagram/Dominika BlonskaPersonal trainer Dominika Blonska has formulated the ‘BB plan’ to help you lose weight […]
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva ® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type
The quiet trends reshaping ag: a field guide for builders, backers, and business leaders
Mark S. Brooks is a venture strategist and corporate innovation leader with deep experience across agtech, biotech, climate, and entrepreneurship. A former academic climate scientist-turned-investor, Mark has deployed over $75 million in venture capital globally, led FMC Ventures, invested at Syngenta Ventures, and founded an agtech startup. While exploring his next senior leadership role, Mark […]
Efficacy and safety of danuglipron (PF‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study
Abstract Aims This randomized, double-blind, placebo-controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity. Materials and Methods Eligible participants (aged 18–75 years; with obesity, without diabetes) were randomized to receive danuglipron or placebo twice daily (BID) for 26 […]
Diabetic patients taking GLP-1s may face increased risk of eye disease, study suggests
Diabetes is the leading cause of vision loss in people between 18 and 64 years old, according to the American Diabetes Association — and the best way to prevent this is to control blood sugar levels. Glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic and Mounjaro, have become popular medications for controlling diabetes and treating […]
The rise of GLP-1 drugs: Transforming weight loss treatment
Discover how GLP-1 drugs are reshaping weight loss and treatment horizons.
Strict rules as GPs start to prescribe weight loss jab Mounjaro
NHS England says the first patients able to get the jab will be those most in need.